Latest Biotech News

Pfizer disclosed the death of a participant in a long‑term extension trial of Hympavzi (marstacimab), reporting a cerebellar infarction followed by cerebral hemorrhage. The company communicated...

Daiichi Sankyo voluntarily placed a partial recruitment and enrollment hold on the phase III IDeate‑Lung02 study of the antibody‑drug conjugate ifinatamab deruxtecan following a...

Shionogi agreed to acquire global rights to edaravone from Tanabe Pharma for $2.5 billion, securing an approved amyotrophic lateral sclerosis (ALS) therapy marketed in the U.S. as Radicava (oral...

Minimal residual disease (MRD) testing saw multiple high‑profile trial readouts and commercial consolidations in 2025, with the Phase III IMvigor011 trial using Natera’s Signatera test presenting...

The U.S. Food and Drug Administration approved Novo Nordisk’s oral formulation of semaglutide, branded as the Wegovy pill, for chronic weight management and cardiovascular risk reduction. The...

AstraZeneca agreed to acquire ex‑China rights to Jacobio Pharmaceuticals’ phase I pan‑KRAS inhibitor JAB‑23E73 in a deal worth up to $1.915 billion, with an immediate $100 million up‑front...

Boehringer Ingelheim struck an agreement with the U.S. administration to join the TrumpRx.gov direct‑purchase platform and pledged $10 billion of investment into U.S. research, development and...

Shionogi & Co. will acquire global rights to edaravone, an FDA‑approved therapy for amyotrophic lateral sclerosis (marketed as Radicava ORS and I.V. Radicava in the U.S.), under a $2.5 billion...

Federal prosecutors unsealed charges against six individuals alleging insider trading and stock manipulation that targeted biopharma companies and generated roughly $41 million in illicit gains....

Samsung Biologics’ U.S. subsidiary signed a definitive agreement to acquire Human Genome Sciences’ Rockville, Maryland manufacturing site from GSK for $280 million, marking Samsung’s first U.S....

Japan’s regulators approved Guardant Health’s Guardant360 companion diagnostic to detect ESR1 mutations and guide use of Eli Lilly’s Inluriyo in breast cancer patients. The Japanese clearance...

Harbour Biomed announced a collaboration with Bristol Myers Squibb to develop multispecific antibodies, receiving about $90 million up front and potential milestones that could exceed $1 billion....

Aktis Oncology filed for an initial public offering to raise capital for clinical development of its miniprotein radiopharmaceuticals, following partnerships and investments from Eli Lilly,...

Multiple late‑stage readouts in 2025 strengthened the commercial and clinical case for minimal residual disease (MRD) testing; the Phase III IMvigor011 trial used Natera’s tumor‑informed Signatera...

The FDA approved an oral formulation of Novo Nordisk’s GLP‑1 obesity drug, and the company is preparing a broad commercial launch. The approval makes Wegovy the first oral GLP‑1 cleared...

Boehringer Ingelheim and Boston startup Rectify Pharmaceuticals signed a research and licensing agreement to advance oral therapies for chronic kidney disease, a partnership that could deliver up...

AstraZeneca paid $100 million upfront to outlicense ex‑China rights for Jacobio Pharmaceuticals’ phase I pan‑KRAS inhibitor JAB‑23E73 in a deal that can total roughly $1.9 billion. AstraZeneca...

Windward Bio acquired ex‑China rights to Qyuns Therapeutics’ clinical‑stage bispecific WIN027 (QX027N), a TSLP/IL‑13 dual antibody, in a deal that could reach $700 million. Windward said the...

Gilead Sciences exercised its option to license two helicase‑primase inhibitors for recurrent genital herpes from Assembly Biosciences, paying $35 million upfront. The compounds, ABI‑1179 and...

Aktis Oncology filed for an initial public offering to finance clinical development of miniprotein radioconjugates, including a Nectin‑4‑targeting candidate in U.S. phase 1b testing. The company,...